Overall, based on our analysis, we propose that GLP-1 RAs are considered as an optimal class of hypoglycemic drugs for implementing safer intensive glycemic treatment in patients with T2DM, while SGLT2i may be a suitable option, particularly for patients with acute or previous MI, no matter with T2DM. The gene discussed is GCG; the disease is type 2 diabetes mellitus.